Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant docetaxel-platinum with or without radiotherapy for resected high-risk gastric cancer
ACTRN12609000757213Phase 3Completed
- Sponsor
- HeCOG
- Start
- Apr 2002
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel, carboplatin and cisplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by HeCOG. Primary endpoint: Overall survival. Started Apr 2002; status: completed.
02
Drugs
docetaxelcarboplatincisplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ACTRN12609000757213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000757213.